Palavras-chave
Cannabis
Ansiedade
Adultos
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Debater os efeitos terapêuticos da Cannabis no tratamento da ansiedade em adultos. Métodos: Trata-se de uma revisão integrativa, realizada nas bases de dados National Library of Medicine (MEDLINE PubMed), Scientific Electronic Library Online (SciELO), e Scopus, a partir dos descritores em saúde e seus correspondentes em inglês “Cannabis”, “maconha medicinal”, “canabinoide”, “ansiedade” e “adultos”. Foram escolhidos artigos científicos publicados nos últimos 5 anos(2019-2024), em open access, somente estudos primários, publicados em revistas indexadas, com idioma em inglês, português ou espanhol. Resultados: Foram encontrados 5154 artigos, dos quais 5139 foram excluídos por não atenderem os critérios previamente estabelecidos, totalizando 15 artigos científicos para serem lidos e analisados na íntegra. Verificou-se a evidência de efeitos positivos, negativos e neutros no uso da Cannabis para tratamento da ansiedade. Considerações finais: A Cannabis medicinal pode ajudar a reduzir sintomas de ansiedade em adultos, mas sua eficácia varia conforme a composição, o tempo de uso e a expectativa do paciente. Dessa forma, são necessários mais estudos para conclusões mais precisas sobre seus efeitos em diferentes organismos.
Referências
ANVISA. Agência Nacional de Vigilância Sanitária. Boletim Saúde e Economia nº 10: Transtornos de Ansiedade. Brasília, DF: ANVISA, 2013; 1: 1-5.
ALTMAN D, et al. Principais itens para relatar Revisões sistemáticas e Meta-análises: a recomendação prisma. Epidemiologia e Serviços de Saúde, 2015; 24: 335-342.
BARANOVIĆ G. Compreendendo as propriedades conformacionais, eletrônicas e vibracionais do tetrahidrocanabinol (THC) e do canabidiol (CBD). Semelhanças e diferenças farmacofóricas. Journal of Molecular Structure, 2018; 1244: 130945.
BOAS G e REZENDE M. Discussão sobre o acesso aos medicamentos derivados da Cannabis à luz da Inovação em Saúde no Brasil. Revista Fitos Eletrônica, 2020; 14: 259-284.
BRASIL, Ministério da Saúde. Transtornos de ansiedade podem estar relacionados a fatores genéticos, 2022.
BURDINSKI D, et al. Impact of year-long cannabis use for medical symptoms on brain activation during cognitive processes. Cold Spring Harbor Laboratory, 2024; 24306516.
CUTTLER C, et al. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Scientific Reports, 2024; 14(1): 16163.
DAS A, et al. Perceptions, Experiences, and Patterns of Cannabis Use in Individuals with Mood and Anxiety Disorders in the Context of Cannabis Legalization and Medical Cannabis Program in Canada – A Qualitative Study. Pharmacopsychiatry, 2024; (3): 141-151.
DUGOSH KL, et al. Anxiety severity and prescription medication utilization in first-time medical marijuana users. Journal Of Affective Disorders Reports, 2023; 14: 100671.
ELSAID S, et al. Motivations for Cannabis Use in Individuals with Social Anxiety Disorder (SAD). Brain Sciences, 2023; 13: 1698.
FONSECA FR, et al. THE ENDOCANNABINOID SYSTEM: physiology and pharmacology. Alcohol And Alcoholism, 2004; 40: 2-14.
HAFKAMP F, et al. Altas expectativas pré-operatórias precedem expectativas não cumpridas e melhora clínica após substituição total de quadril e joelho. The Journal of arthroplasty. 2020; 35: 1806-1812.
HOCH E, et al. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. European Archives Of Psychiatry And Clinical Neuroscience, 2019; 269: 87-105.
KALABA M, et al. Authorization Patterns, Safety, and Effectiveness of Medical Cannabis in Quebec. Cannabis And Cannabinoid Research, 2021; 6: 564-572.
KENDZOR DE, et al. Characteristics of adults with a medical cannabis license, reasons for use, and perceptions of benefit following medical cannabis legalization in Oklahoma. Preventive Medicine Reports, 2022; 27: 101777.
LEE C, et al. Generalized Anxiety Disorder 7-Item (GAD-7) Scores in Medically Authorized Cannabis Patients—Ontario and Alberta, Canadá. The Canadian Journal Of Psychiatry, 2021; 67: 470-480.
MACKIE K. Distribution of Cannabinoid Receptors in the Central and Peripheral Nervous System. Handbook Of Experimental Pharmacology, 2005; 168: 299-325.
MANNION AF, et al. Great expectations: really the novel predictor of outcome after spinal surgery? Spine, 2009; 34(15): 1590-1599.
MARTÍN-SANTOS R, et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Current pharmaceutical design, 2012; 18(32): 4966-79.
MENG H, et al. Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in chronic pain patients. Canadian Journal Of Anesthesia/Journal Canadien D'Anesthésie, 2012; 68: 633-644.
MONDLOCH MV, et al. Does how you do depend on how you think you'll do? A systematic review of the evidence for a relation between patients' recovery expectations and health outcomes. CMAJ, 2001; 165(2): 174-9.
MOSANDL CF, et al. Cannabis use and its association with psychopathological symptoms in a Swiss adult population: a cross-sectional analysis. Frontiers In Public Health, 2024; 12: 213-685.
MURPHY M, et al. A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance. Neuropsychopharmacology Reports, 202; 44: 129-142.
NAYA NM, et al. Molecular and Cellular Mechanisms of Action of Cannabidiol. Molecules, 2023; 28: 5980.
PINTORI N, et al. THC e CBD: Vilão versus Herói? Insights sobre a Exposição Adolescente. International Journal of Molecular Sciences. Disponível em: https ://www.cannabisesaude.com.br/thc-mocinho-ou-vilao/. Acesso em: 24 set. 2024.
RIFKIN-ZYBUTZ R, et al. Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the uk medical cannabis registry. Springer Science and Business Media LLC. Psychopharmacology, 2023; 240: 1735-1745.
ROSENTHAL MS, et al. Demographics, Perceptions, and Use of Medical Marijuana among Patients in Florida. Medical Cannabis And Cannabinoids, 2020; 4: 13-20.
SADAKA A, et al. Effects of inhaled cannabis high in Δ9-THC or CBD on the aging brain: a translational mri and behavioral study. Frontiers In Aging Neuroscience, 20233; 15: 327-345.
SHANNON S, et al. Cannabidiol in Anxiety and Sleep: a large case series. The Permanente Journal, 2019; 23: 18-41.
SHARPE L, et al. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. Journal Of Translational Medicine, 2020; 18: 327-345.
SOLOWIJ N, et al. A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. European Archives of Psychiatry and Clinical Neuroscience, 2019; 269, 17-35.
SOUZA MT, et al. Integrative review: what is it? how to do it? FapUNIFESP (SciELO). Einstein (São Paulo), 2010; 8: 102-106.
SPINELLA TC, et al. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study. Psychopharmacology, 2021; 238: 1965-1977.
SZUHANY KL, SIMON NM. Anxiety Disorders. American Medical Association (AMA). Jama, 2022; 328: 2431-27.
TOUSSAINT A, et al. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). Journal Of Affective Disorders, 2020; 265: 395-401.
VOLKOW ND, et al. Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: a review. Jama Psychiatry, 2016; 73: 292.